Eton Pharmaceuticals Files 8-K
Ticker: ETON · Form: 8-K · Filed: Nov 7, 2024 · CIK: 1710340
Sentiment: neutral
Topics: 8-K, SEC Filing, Financials
TL;DR
Eton Pharma filed an 8-K, likely routine docs. No major news yet.
AI Summary
Eton Pharmaceuticals, Inc. filed an 8-K on November 7, 2024, reporting on events that occurred on November 5, 2024. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text.
Why It Matters
This 8-K filing indicates Eton Pharmaceuticals is providing updates or submitting required financial documents to the SEC, which is standard corporate disclosure.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and financial exhibits, not indicating any immediate material adverse events.
Key Numbers
- 001-38738 — SEC File Number (Identifies the company's filing history with the SEC.)
- 37-1858472 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- 20241107 (date) — Filing Date
- 20241105 (date) — Earliest Event Date
- 001-38738 (company) — SEC File Number
- 37-1858472 (company) — IRS Employer Identification Number
FAQ
What specific 'Other Events' are being reported by Eton Pharmaceuticals in this 8-K?
The provided text does not detail the specific 'Other Events' beyond stating that this is the item being reported.
What is the significance of filing 'Financial Statements and Exhibits' on an 8-K?
This indicates the company is submitting required financial documents or exhibits as part of its SEC reporting obligations.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on November 5, 2024.
What is Eton Pharmaceuticals' principal executive office address?
The principal executive offices are located at 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010-7208.
What is Eton Pharmaceuticals' standard industrial classification?
The company's Standard Industrial Classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 9.5 · Accepted 2024-11-07 07:05:27
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
Filing Documents
- eton20241105_8k.htm (8-K) — 26KB
- ex_743588.htm (EX-99.1) — 9KB
- 0001437749-24-033729.txt ( ) — 167KB
- eton-20241105.xsd (EX-101.SCH) — 3KB
- eton-20241105_def.xml (EX-101.DEF) — 11KB
- eton-20241105_lab.xml (EX-101.LAB) — 15KB
- eton-20241105_pre.xml (EX-101.PRE) — 11KB
- eton20241105_8k_htm.xml (XML) — 3KB
01: Other Events
Item 8.01: Other Events On November 7, 2024, Eton Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent Application No. 18/443,889, now U.S. Patent No. 12,133,914, for ET-400, a proprietary patented formulation of liquid hydrocortisone. The patent, which expires in 2043, covers a method of using hydrocortisone oral liquid formulations and is expected to be listed in the U.S. Food and Drug Administration's (FDA) Orange Book upon the product's approval. Eton received its first patent (US 11,904,046) for ET-400 in February 2024 and the Company has an additional U.S. patent application under review related to the product. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. 2
01: Financial Statements and Exhibits
Item 9.01: Financial Statements and Exhibits Exhibit No. Description Exhibit 99.1 Press Release dated November 7, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 7, 2024 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 4